It isn't a bad business model, but the U.S. market is largely saturated. Competition is fierce, and more and more ways to buy medication now exist, exacerbating the issue. They include grocery stores, ...

Pfizer has been a big name in healthcare for decades, but it has been a largely underwhelming investment over the past 10 ...

Retail Gazette takes a closer look at Boots' new private equity owner and what the deal means for the future of the health ...

Walgreens Boots Alliance (WBA) closed at $11.16 in the latest trading session, marking a +0.95% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.58%.

The stock rose 0.6% in premarket trading. U.S. retail pharmacy sales were $30.72 billion, up from $28.5 billion in the prior year's quarter, to mark the ninth straight quarter of year-over-year ...

Walgreens Boots Alliance's fiscal third-quarter results came in above FactSet consensus estimates. Total revenue of $39 billion was up 7.2% year over year, and adjusted earnings per share declined ...

In the latest market close, Walgreens Boots Alliance (WBA) reached $11.20, with a -0.44% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.41 ...

Walgreens Boots Alliance continues to see weakness in U.S. front-end sales, says Chief Executive Tim Wentworth Last Updated: June 26, 2025 at 8:57 a.m. ET First Published: June 26, 2025 at 7:14 a ...